Regeneron Pharmaceuticals has seen a stock surge of approximately 4.84%, closing at $779.36, with a 9% gain year-to-date. The company generated $4 billion in free cash flow over the past year and is projected to reach $6.4 billion by 2029, while Morgan Stanley has raised its price target for Regeneron to $768. Despite these successes, analysts claim Regeneron remains undervalued, with an intrinsic value estimation of $1,604 per share.
“Regeneron Pharmaceuticals · gained · percentage · 4.84%”
“Regeneron Pharmaceuticals · gained · percentage · +4.84%”
“Regeneron Pharmaceuticals · gained · percentage · 4.84%”
“Regeneron's share of profits · has increased · underscoring the strength of the collaboration”
“REGN stock · has traded between · $476.49 and $790.98 over the past year”
“REGN stock · closed yesterday's trading at · $779.36, up 1.48%”
“Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) · is included among · the 13 Best Debt Free Dividend Stocks to Buy Now”
“Morgan Stanley analyst Terence Flynn · raised the firm’s price target on · Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) · $768”
“Dupilumab · is being jointly developed by · Sanofi and Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)”
“Sanofi and Regeneron · continue to study · dupilumab in a wide range of diseases”
“Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) · is a biotechnology company · focused on discovering, developing, and commercializing medicines for serious diseases”
“Regeneron Pharmaceuticals · has climbed · price · 3.6% over the last week”
